Articles Tagged With: oseltamivir
-
Oseltamivir for Pediatric Inpatients with Influenza
A large study of children hospitalized with influenza clearly shows that oseltamivir given at or near the time of admission is effective in reducing the duration of hospitalization, reducing the requirement for intensive care, and reducing subsequent readmissions within the week after discharge.
-
Baloxavir Marboxil (Xofluza)
Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.
-
Viral Influenza Infection and Complications: A Pediatric-focused Review
As influenza season approaches, it is important that clinicians prepare themselves with the current literature on clinical presentation, best and most rapid diagnostic testing, and treatment strategies in pediatric patients. The literature shows that antiviral agents are underutilized in children, a critical issue for this vulnerable population. The authors provide insight and evidence for diagnostic and therapeutic practice for the upcoming influenza season.
-
Echinacea-based Infusion Noninferior to Oseltamivir in Early Influenza Treatment
Echinacea Hotdrink was found to be as effective as oseltamivir as early treatment intervention of clinically diagnosed and lab-confirmed influenza virus infections and had fewer adverse effects.